Calendario›MGNX›vobramitamab duocarmazine
vobramitamab duocarmazine
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Ensayo de MACROGENICS INC en Advanced Solid Tumor · Castration-Resistant Prostatic Cancer · Malignant Melanoma · Pancreatic Ductal Carcinoma · Hepatocellular Cancer · Epithelial Ovarian Cancer · Renal Cell Carcinoma (del registro, en inglés).
Más ensayos de: Tumor sólido avanzado · Melanoma maligno · Cáncer epitelial de ovario · Carcinoma de células renales.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 31
- Centros
- 10
- Fin del objetivo primario
- jun 2025
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en abr 2022.
Qué mide
Number of participants with adverse events (AEs) (del registro, en inglés) (hasta 2 años)
Cómo lo describe el promotor
En el documentoEn inglés, del registroStudy CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled. Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years. Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD). Participants will be followed for safety throughout the study. .
Más ensayos de MGNX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| MGC028 | Fase 1 | Reclutando pacientes | nov 2026 (prevista) |
| MGD024 | Fase 1 | En marcha, sin reclutar | nov 2026 (prevista) |
| Lorigerlimab | Fase 2 | Reclutando pacientes | jul 2027 (prevista) |
| MGC026 Dose Escalation | Fase 1 | Reclutando pacientes | may 2028 (prevista) |
| MGC030 | Fase 1 | Aún sin reclutar | sep 2028 (prevista) |
| lorigerlimab | Fase 2 | Completado | feb 2026 (real) |
Todos los de MGNX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05293496), actualizada en oct 2025.